[1]胡伟男,蔡文婷,邹爱琪,等.精氨酸-甘氨酸-天冬氨酸修饰的星型高分子负载雷珠单抗对脉络膜新生血管靶向治疗作用[J].眼科新进展,2021,41(2):130-135.[doi:10.13389/j.cnki.rao.2021.0027]
　HU Weinan,CAI Wenting,ZOU Aiqi,et al.Targeted therapy effect of arginine-glycine-aspartate modified star polymer loaded ranibizumab on choroidal neovascularization[J].Recent Advances in Ophthalmology,2021,41(2):130-135.[doi:10.13389/j.cnki.rao.2021.0027]
点击复制

精氨酸-甘氨酸-天冬氨酸修饰的星型高分子负载雷珠单抗对脉络膜新生血管靶向治疗作用/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
41卷
期数:
2021年2期
页码:
130-135
栏目:
实验研究
出版日期:
2021-02-05

文章信息/Info

Title:
Targeted therapy effect of arginine-glycine-aspartate modified star polymer loaded ranibizumab on choroidal neovascularization
作者:
胡伟男; 蔡文婷; 邹爱琪; 朱美江; 刘畅; 于靖
232001　安徽省淮南市，安徽理工大学（胡伟男，于靖）；200072　上海市，同济大学附属上海市第十人民医院眼科（蔡文婷，邹爱琪，朱美江，于靖）；211166　江苏省南京市，南京医科大学（刘畅）
Author(s):
HU Weinan1; CAI Wenting2; ZOU Aiqi2; ZHU Meijiang2; LIU Chang3; YU Jing1; 2
1.Anhui University of Science and Technology,Huainan 232001,Anhui Province，China
2.Department of Ophthalmology,Shanghai Tenth People’s Hospital of Tongji University,Shanghai 200072,China
3.Nanjing Medical University,Nanjing 211166,Jiangsu Province，China
关键词:
年龄相关性黄斑变性; 脉络膜新生血管; 纳米颗粒; 雷珠单抗; 生物安全性
Keywords:
age-related macular degeneration; choroidal neovascularization; nanoparticles; ranibizumab; biosafety
分类号:
R773.4
DOI:
10.13389/j.cnki.rao.2021.0027
文献标志码:
A
摘要:
目的　探讨精氨酸-甘氨酸-天冬氨酸（RGD）修饰的聚乙二醇星型高分子（S-PEG）负载雷珠单抗（RBZ）通过静脉注射方式对激光诱导小鼠脉络膜新生血管（CNV）的靶向治疗作用。方法　分别采用Nano-ZS型纳米粒度分析仪及Zeta电位分析仪对合成的材料S-PEG-ICG-RGD-RBZ NPs（SPIRR NPs）进行表征测试，应用SPIRR NPs分别对人视网膜色素上皮细胞系ARPE-19以及经血管内皮生长因子（VEGF）诱导后的人脐静脉内皮细胞（HUVEC）进行干预，CCK-8法检测细胞毒性，管腔形成实验检测管腔形成情况。建立C57BL/6小鼠CNV模型，尾静脉注射SPIRR NPs后行眼底照相、眼底血管造影检查，并对CNV面积进行测量，检测小鼠肝、肾功能及电解质水平变化以观察SPIRR NPs在体内的生物安全性。结果　成功制备材料SPIRR NPs并对其进行表征，在所研究的浓度范围内，SPIRR NPs具有良好的体外安全性。在HUVEC管腔形成实验中，正常对照组、VEGF干预组、低浓度治疗组、高浓度治疗组管腔节数分别为55.00±16.00、110.00±13.00、44.67±14.36及25.33±17.00，管腔节点数分别为16.00±4.58、31.67±5.51、12.67±5.03及8.00±5.20，管腔节段数分别为20.67±7.37、45.33±8.08、14.33±6.03及7.67±6.66，相对管腔长度分别为1.00±0.00、1.51±0.08、0.97±0.18及0.75±0.15。与正常对照组相比，VEGF干预组的管腔节数、节点数、节段数及相对管腔长度均有大幅度增加，两治疗组各指标均较VEGF干预组显著降低（均为P<0.05）。静脉注射后，脉络膜ICGA可见SPIRR NPs靶向至CNV病灶部位并长期留存，FFA可见荧光渗漏信号减弱， RPE-脉络膜-巩膜铺片可见CNV病灶面积明显缩小。结论　RGD修饰的S-PEG作为一种强有力的载体，可以将抗VEGF药物运送到CNV区域，并且其具有良好的细胞相容性，在CNV治疗中具有很大的应用潜力。
Abstract:
Objective　To investigate the targeted therapeutic effect of arginine-glycine-aspartate (RGD)-modified star shaped polymer (S-PEG) loaded with ranibizumab (RBZ) on laser-induced choroidal neovascularization (CNV) in mice.Methods　Nano-ZS nanoparticle size analyzer and Zeta potential analyzer were used to characterize S-PEG-ICG-RGD-RBA NPs (SPIRR NPs). SPIRR NPs was applied to intervene ARPE-19 cells and human umbilical vein epithelial cells (HUVEC) induced by vascular endothelial growth factor (VEGF). We used CCK-8 method to detect cytotoxicity and cell tubule formation assay to detect lumen formation. After the CNV model of C57BL / 6 mice was established and intravenous injection SPIRR NPs, fundus photography and fundus angiography were performed, and CNV area was also measured. Besides, the liver and kidney functions and electrolyte levels were detected to observe the biological safety of SPIRR NPs in vivo.Results　SPIRR NPs was successfully prepared and characterized. Within the concentration range studied, SPIRR NPs had shown safety in vitro and could inhibit VEGF induced catheter formation. In HUVEC tubule formation assay, the lumen section numbers of the normal control group, the VEGF-intervention group, the low-concentration therapy group and the high-concentration therapy group were 55.00±16.00, 110.00±13.00, 44.67±14.36 and 25.33±17.00. Besides, the number of lumen nodes were 16.00±4.58, 31.67±5.51, 12.67±5.03 and 8.00±5.20, the number of lumen segments were 20.67±7.37, 45.33±8.08, 14.33±6.03 and 7.67±6.66 and the relative length of lumens were 1.00±0.00, 1.51±0.08, 0.97±0.18 and 0.75±0.15. Compared with the normal control group, the number of lumen sections, lumen nodes, lumen segments and the relative length of lumens of the VEGF- intervention group had shown an obviously increase. Notably, these parameters of the two therapy groups was much lower than those of the VEGF- intervention group（all P<0.05）. After intravenous injection, SPIRR NPs were observed to target to the lesion site and remain for a long time by choroidal indocyanine green angiography. Fluorescence leakage signal was decreased in fundus fluorescein angiography, and CNV lesion area was significantly reduced by RPE-choroidal-sclera lamination.Conclusion　As a powerful carrier, RGD modified S-PEG can deliver anti-VEGF drugs to CNV region and shows good cytocompatibility, which has great potential in the treatment of CNV.

参考文献/References:

［1］　BHUACHALLA B N,MCGARRIGLE C A,O’LEARY N,AKUFFO K O,PETO T,BEATTY S,et al.Orthostatic hypertension as a risk factor for age-related macular degeneration:Evidence from the Irish longitudinal study on ageing［J］.Exp Gerontol,2018,106:80-87.
［2］　KNOBBE C A,STOJANOSKA M.The displacing foods of modern commerce are the primary and proximate cause of age-related macular degeneration:A unifying singular hypothesis［J］.Med Hypotheses,2017,109:184-198.
［3］　ROSSATO F A,SU Y,MACKEY A,NG Y S E.Fibrotic changes and endothelial-to-mesenchymal transition promoted by VEGFR2 antagonism alter the therapeutic effects of VEGFRA pathway blockage in a mouse model of choroidal neovascularization［J］.Cells,2020,9(9):2057.
［4］　LIU Y,KANDA A,LIU Y,KANDA A,WU D,ISHIZUKA E T,et al.Suppression of choroidal neovascularization and fibrosis by a novel RNAi therapeutic agent against (pro)renin receptor［J］.Mol Ther Nucleic Acids,2019,17:113-125.
［5］　JIANG P,CHOI A,SWINDLE-REILLY K E.Controlled release of anti-VEGF by redox-responsive polydopamine nanoparticles［J］.Nanoscale,2020,12(33):17298-17311.
［6］　MALONEY M H,PAYNE S R,HERRIN J,SANGARALINGHAM L R,SHAH N D,BARKMEIER A J.Risk of systemic adverse events after intravitreal bevacizumab,ranibizumab,and aflibercept in routine clinical practice［J］.Ophthalmology,2020,Online ahead of print.
［7］　RONDON E P,BENABDOUN H A,VALLIRES F,SEGALLA P M,TIERA M J,BENDERDOUR M,et al.Evidence supporting the safety of pegylated diethylaminoethyl-chitosan polymer as a nanovector for gene therapy applications［J］.Int J Nanomedicine,2020,15:6183-6200.
［8］　SURI R,NEUPANE Y R,JAIN G K,KOHLI K.Recent theranostic paradigms for the management of age-related macular degeneration［J］.Eur J Pharm Sci,2020,153:105489.
［9］　NAGARAJ R,STACK T,YI S,MATHEW B,SHULL K,SCOTT E A,et al.High density display of an anti-angiogenic peptide on micelle surfaces enhances their inhibition of αvβ3 integrin-mediated neovascularization in vitro［J］.Nanomaterials (Basel),2020,10(3):581.
［10］　JACOB D,JOAN T M,TOMLINS P,SAHOTA TARSEM S.Synthesis and identification of FITC-insulin conjugates produced using human insulin and insulin analogues for biomedical applications［J］.J Fluoresc,2016,26(2):617-629.
［11］　HU Y,LIN L,CHEN J,HAO K,ZHANG S,GUO X,et al.Highly enhanced antitumor immunity by a three-barreled strategy of the l-arginine-promoted nanovaccine and gene-mediated PD-L1 blockade［J］.ACS Appl Mater Interfaces,2020,12 (37):41127-41137.
［12］　LI T,HE F,LIU B,JIA T,SHAO B,ZHAO R,et al.In situ synthesis of FeOCl in hollow dendritic mesoporous organosilicon for ascorbic acid-enhanced and MR imaging-guided chemodynamic therapy in neutral pH conditions.［J］.ACS Appl Mater Interfaces,2020,12(51):56886-56897.
［13］　ZHAO Y,WANG H,YANG Y,JIA W,SU T,CHE Y,et al.Mannose-modified liposome co-delivery of human papillomavirus type 16 E7 peptide and CpG oligodeoxynucleotide adjuvant enhances antitumor activity against established large TC-1 grafted tumors in mice［J］.Int J Nanomedicine,2020,15:9571-9586.
［14］　FISCHER D,LI Y,AHLEMEYER B,KRIEGLSTEIN J,KISSEL T.In vitro cytotoxicity testing of polycations:influence of polymer structure on cell viability and hemolysis［J］.Biomaterials,2003,24:1121-1131.
［15］　BARRIOS-GUMIEL A,SNCHEZ-NIEVES J,PEDZIWIATR-WERBICKA E,ABASHKIN V,SHCHARBINA N,SHCHARBIN D,et al.Effect of PEGylation on the biological properties of cationic carbosilane dendronized gold nanoparticles［J］.Int J Pharm,2020,573:118867.
［16］　ZHONG R,ZHONG Q,HUO M,YANG B,LI H.Preparation of biocompatible nano-ZnO/chitosan microspheres with multi-functions of antibacterial,UV-shielding and dye photodegradation［J］.Int J Biol Macromol,2020,146:939-945.
［17］　VANGAVETI S,DAS P,KUMAR V L.Metformin and silymarin afford protection in cyclosporine A induced hepatorenal toxicity in rat by modulating redox status and inflammation［J］.J Biochem Mol Toxicol,2020,35(1):e22614.
［18］　AL H A J,ZEN A.In vitro models to study the regulatory roles of retinoids in angiogenesis［J］.Methods Mol Biol,2019,2019:73-83.
［19］　ZHANG Y,HUANG Q,TANG M,ZHANG J,FAN W.Complement factor H expressed by retinal pigment epithelium cells can suppress neovascularization of human umbilical vein endothelial cells:An in vitro study［J］.PLoS One,2015,10:e0129945.
［20］　SUZUKI R,YAMAMOTO H,NGAN C Y,OHTSUKA M,KITANI K,UEMURA M,et al.Inhibition of angiopoietin 2 attenuates lumen formation of tumour-associated vessels in vivo［J］.Int J Oncol,2013,43 (5):1447-1455.
［21］　SHAH R S,SOETIKNO B T,LAJKO M,FAWZI A A.A mouse model for laser-induced choroidal neovascularization［J］.J Vis Exp,2015,(106):e53502.
［22］　RICCI F,BANDELLO F,NAVARRA P,STAURENGHI G,STUMPP M,ZARBIN M.Neovascular age-related macular degeneration:Therapeutic management and new-upcoming approaches［J］.Int J Mol Sci,2020,21 (21):8242.
［23］　YAN Z,SHI H,ZHU R,LI L,QIN B,KANG L,et al.Inhibition of YAP ameliorates choroidal neovascularization via inhibiting endothelial cell proliferation［J］.Mol Vis,2018,24:83-93.

相似文献/References:

[1]范姜砾 王雨生 张鹏.湿性年龄相关性黄斑变性患者血浆中相关抗氧化酶水平测定[J].眼科新进展,2012,32(5):000.
[2]王毅 李罗翔 李娟 曾庆华.ApoE基因缺失小鼠视网膜及Bruch膜组织形态观察[J].眼科新进展,2013,33(1):000.
[3]徐新荣 仲路 黄冰林 魏源华 周欣 王玲 王富强.年龄相关性黄斑变性血浆蛋白质组学初步研究[J].眼科新进展,2013,33(2):000.
[4]王毅 李罗翔 李进辉 李娟 曾庆华.血脂异常ApoE基因缺失小鼠视网膜色素上皮细胞胞浆内黑色素和脂褐素的改变[J].眼科新进展,2013,33(7):000.
[5]许瑶 曾骏文.近视眼药物治疗研究进展[J].眼科新进展,2013,33(7):000.
[6]许琴 黄亮 林素香 郑水华 肖煜晨 王雅丽.激光诱导小鼠脉络膜新生血管中膜攻击物与血管生长因子的表达[J].眼科新进展,2013,33(8):000.
[7]罗文婷 孙大卫.血管黏附蛋白-1在眼科疾病中的研究进展[J].眼科新进展,2013,33(8):000.
[8]詹文捷 梁丽娜 唐由之.骨髓来源细胞参与脉络膜新生血管形成的研究进展[J].眼科新进展,2012,32(1):000.
[9]陈丽娟 苗林.重组人血管内皮抑素对脉络膜新生血管的抑制作用[J].眼科新进展,2012,32(10):000.
[10]金昱 石安娜 刘维锋 石浔 王永波.频域OCT在光动力疗法治疗病理性近视脉络膜新生血管中的应用[J].眼科新进展,2012,32(10):000.
[11]党亚龙 陈彬川 穆雅林 赵满丽 朱豫.i-MP对产生2型脉络膜新生血管的年龄相关性黄斑变性患者视力及黄斑厚度的影响[J].眼科新进展,2013,33(2):000.
[12]栾兰 姚勇.湿性年龄相关性黄斑变性的治疗进展[J].眼科新进展,2013,33(4):000.
[13]胡艳红 祁明信 郭娜 陈胜 柯发杰.渗出型年龄相关性黄斑变性患者外周血CCR3的表达[J].眼科新进展,2013,33(11):000.
[14]魏菁,黄厚斌. 吲哚青绿介导的光栓塞治疗黄斑中心凹下脉络膜新生血管[J].眼科新进展,2014,34(9):842.[doi:10.13389/j.cnki.rao.2014.0232]
[15]于靖,刘晴雨,吴岩.阿司匹林是年龄相关性黄斑变性的危险因素[J].眼科新进展,2014,34(10):901.[doi:10.13389/j.cnki.rao.2014.0249]
[16]朱磊,田晓燕,刘涛.玻璃体内注射康柏西普治疗湿性年龄相关性黄斑变性的临床观察[J].眼科新进展,2017,37(5):473.[doi:10.13389/j.cnki.rao.2017.0120]
　ZHU Lei,TIAN Xiao-Yan,LIU Tao.Intravitreal injection of conbercept for wet age-related macular degeneration[J].Recent Advances in Ophthalmology,2017,37(2):473.[doi:10.13389/j.cnki.rao.2017.0120]
[17]卢悦,蔡玲,朱晨,等.人参皂苷RG3对脉络膜新生血管的抑制作用[J].眼科新进展,2017,37(10):922.[doi:10.13389/j.cnki.rao.2017.0234]
　LU Yue,CAI Ling,ZHU Chen,et al.Inhibitory effect of ginsenoside RG3 on choroidal neovascularization[J].Recent Advances in Ophthalmology,2017,37(2):922.[doi:10.13389/j.cnki.rao.2017.0234]
[18]邵毅,周琼.年龄相关性黄斑变性诊断与治疗规范——2018年英国专家共识解读[J].眼科新进展,2019,39(11):1001.[doi:10.13389/j.cnki.rao.2019.0229]
　SHAO Yi,ZHOU Qiong.Diagnosis and treatment of age-related macular degeneration:An interpretation of British National Institute for Health and Care Excellence (NICE) in 2018[J].Recent Advances in Ophthalmology,2019,39(2):1001.[doi:10.13389/j.cnki.rao.2019.0229]
[19]付燕,张月玲,王丽英,等.湿性年龄相关性黄斑变性患者抗VEGF治疗无效的因素分析和视功能预后[J].眼科新进展,2021,41(3):254.[doi:10.13389/j.cnki.rao.2021.0053]
　FU Yan,ZHANG Yueling,WANG Liying,et al.Factors and outcomes associated with failure to anti-VEGF treatment in patients with wet age-related macular degeneration[J].Recent Advances in Ophthalmology,2021,41(2):254.[doi:10.13389/j.cnki.rao.2021.0053]
[20]胡梦燕,邵毅,裴重刚.年龄相关性黄斑变性患者色素上皮形态与最佳矫正视力的关系研究进展[J].眼科新进展,2021,41(8):797.[doi:10.13389/j.cnki.rao.2021.0167]
　HU Mengyan,SHAO Yi,PEI Chonggang.Research progress on the relationship between pigment epithelium morphology and best corrected visual acuity in patients with age-related macular degeneration[J].Recent Advances in Ophthalmology,2021,41(2):797.[doi:10.13389/j.cnki.rao.2021.0167]

备注/Memo

备注/Memo:
上海市自然科学基金资助（编号：19ZR1439500）；中央高校基础研究经费基金资助（编号：22120180509）
更新日期/Last Update: 2021-02-05